BioNTech execs say theyre on track to get their late-stage data on a Covid-19 vaccine partnered with Pfizer into the hands of regulators as early as October.

In their Q2 release Tuesday morning, the biotech reported that investigators could have late-stage data as early as October, and they wont be wasting any time in hustling that over to the FDA.

I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful, said Ugur Sahin, BioNTechs CEO and co-founder.

Unlock this story instantly and join 87,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

More:
UPDATED: Moderna offers steep discount in US supply deal but still takes the crown with close to $2.5B in vaccine contracts - Endpoints News